Cargando…
Drugs to Treat Alcohol Dependence-A Perspective
Despite increased awareness, prevention campaigns, and tighter laws and regulations, alcohol consumption caused an average of 88,000 deaths per year and a burden of $249 billion to the U.S economy in 2010. Only three FDA-approved drugs, disulfiram, naltrexone and acamprosate are available for the tr...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945284/ https://www.ncbi.nlm.nih.gov/pubmed/29756083 |
_version_ | 1783321971993346048 |
---|---|
author | Das, Joydip |
author_facet | Das, Joydip |
author_sort | Das, Joydip |
collection | PubMed |
description | Despite increased awareness, prevention campaigns, and tighter laws and regulations, alcohol consumption caused an average of 88,000 deaths per year and a burden of $249 billion to the U.S economy in 2010. Only three FDA-approved drugs, disulfiram, naltrexone and acamprosate are available for the treatment of alcohol use disorder. These drugs are only effective modestly and patient compliance is a serious issue because of several adverse side effects, necessitating the developments of newer drugs. The current research drug development efforts remains in the identification new alcohol targets and elucidating the molecular mechanism of its action is needed for effective intervention. In addition, current treatment could be improved by testing the existing medications for comorbid conditions using the patient’s genetic background information. |
format | Online Article Text |
id | pubmed-5945284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59452842018-05-10 Drugs to Treat Alcohol Dependence-A Perspective Das, Joydip J Addict Depend Article Despite increased awareness, prevention campaigns, and tighter laws and regulations, alcohol consumption caused an average of 88,000 deaths per year and a burden of $249 billion to the U.S economy in 2010. Only three FDA-approved drugs, disulfiram, naltrexone and acamprosate are available for the treatment of alcohol use disorder. These drugs are only effective modestly and patient compliance is a serious issue because of several adverse side effects, necessitating the developments of newer drugs. The current research drug development efforts remains in the identification new alcohol targets and elucidating the molecular mechanism of its action is needed for effective intervention. In addition, current treatment could be improved by testing the existing medications for comorbid conditions using the patient’s genetic background information. 2016-06-06 2016 /pmc/articles/PMC5945284/ /pubmed/29756083 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License. |
spellingShingle | Article Das, Joydip Drugs to Treat Alcohol Dependence-A Perspective |
title | Drugs to Treat Alcohol Dependence-A Perspective |
title_full | Drugs to Treat Alcohol Dependence-A Perspective |
title_fullStr | Drugs to Treat Alcohol Dependence-A Perspective |
title_full_unstemmed | Drugs to Treat Alcohol Dependence-A Perspective |
title_short | Drugs to Treat Alcohol Dependence-A Perspective |
title_sort | drugs to treat alcohol dependence-a perspective |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945284/ https://www.ncbi.nlm.nih.gov/pubmed/29756083 |
work_keys_str_mv | AT dasjoydip drugstotreatalcoholdependenceaperspective |